Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Income from Continuing Operations (2022 - 2025)

Atara Biotherapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 3406000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 72.94% year-over-year to 3406000.0; the TTM value through Dec 2025 reached 32688000.0, up 138.32%, while the annual FY2025 figure was 32688000.0, 138.32% up from the prior year.
  • Income from Continuing Operations reached 3406000.0 in Q4 2025 per ATRA's latest filing, up from 4303000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 38010000.0 in Q1 2025 to a low of 88105000.0 in Q1 2022.
  • Average Income from Continuing Operations over 4 years is 34830500.0, with a median of 26830500.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: tumbled 485.08% in 2023, then surged 219.71% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 74572000.0 in 2022, then increased by 18.6% to 60699000.0 in 2023, then soared by 79.26% to 12589000.0 in 2024, then skyrocketed by 72.94% to 3406000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Income from Continuing Operations are 3406000.0 (Q4 2025), 4303000.0 (Q3 2025), and 2387000.0 (Q2 2025).